Author:
Tohen Mauricio,McDonnell David P.,Case Michael,Kanba Shigenobu,Ha Kyooseob,Fang Yi Ru,Katagiri Hideaki,Gomez Juan-Carlos
Abstract
BackgroundAtypical antipsychotics are widely used in bipolar mania. However, the
efficacy of atypical antipsychotics in bipolar depression has not been
comprehensively explored.AimsTo evaluate olanzapine monotherapy in patients with bipolar
depression.MethodPatients with bipolar depression received olanzapine (5–20mg/day,
n = 343) or placebo (n = l71) for 6
weeks. The primary outcome was change from baseline to end-point in
Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary
outcomes included: Clinical Global impression - Bipolar Version (CGI-BP)
scale, 17-item Hamilton Rating Scale for Depression (HRSD-17) and Young
Mania Rating Scale (YMRS) scores, and the rate of response (≥50%
reduction in MADRS at end-point), recovery (MADRS ≤12 for ≥4 weeks plus
treatment completion) and remission (MADRS ≤8). The trial was registered
with ClinicalTrials.gov (NCT00510146).ResultsOlanzapine demonstrated: significantly greater
(P<0.04) improvements on MADRS (least-squares mean
change -13.82 v. -11.67), HRSD-17 and YMRS total scores
and all CGI-BP subscale scores v. placebo; significantly
(P≤0.05) more response and remission, but not
recovery; significantly (P<0.01) greater mean
increases in weight, fasting cholesterol and triglycerides; and
significantly more (P<0.001) patients gained ≥7% body
weight.ConclusionsOlanzapine monotherapy appears to be efficacious in bipolar depression.
Additional long-term studies are warranted to confirm these results.
Safety findings were consistent with the known safety profile of
olanzapine.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献